Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06996912

A Study for HSK44459 in Participants With Atopic Dermatitis

A Phase 2 Study Investigating the Efficacy and Safety of HSK44459 Tablet Administered to Participants With Atopic Dermatitis

Status
Active Not Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
150 (estimated)
Sponsor
Xizang Haisco Pharmaceutical Co., Ltd · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess the efficacy and safety of HSK44459 in adults with Atopic Dermatitis

Detailed description

This is a multicenter, randomized, double-blind, parallel group, placebo controlled phase 2 study to assess the efficacy and safety of HSK44459 in adult participants with Atopic Dermatitis.

Conditions

Interventions

TypeNameDescription
DRUGHSK44459HSK44459 will be administered orally twice daily
DRUGPlaceboPlacebo will be administered orally twice daily

Timeline

Start date
2025-05-22
Primary completion
2026-01-20
Completion
2026-03-23
First posted
2025-05-30
Last updated
2026-01-02

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06996912. Inclusion in this directory is not an endorsement.